Lu Xia-Liang, Zhan Rui, Zhao Guang-Ming, Qian Zhen-Hua, Gong Chan-Chan, Li Yan-Qing
Department of Pathology, Suzhou Ninth People's Hospital Affiliated Wujiang Hospital of Nantong University, Suzhou, Jiangsu, China.
J Invest Surg. 2022 Feb;35(2):442-447. doi: 10.1080/08941939.2020.1852344. Epub 2020 Dec 8.
To investigate role and clinical significance of CDK13 in breast cancer patients.
A total of 189 cases of breast cancer were enrolled during March 2013 to March 2015. Immunohistochemistry (IHC) was used for measurement of CDK13, HIF-1α and beclin1. Clinical characteristics of age, BMI, TNM stage, pathological types, and tumor diameter, were recorded. Patients' 5-year overall survival and recurrence were followed up. All patients were followed up for 5 years or to the last follow-up.
The expression levels of CDK13 and HIF-1αin breast cancer tissues were up-regulated and beclin1 was down-regulated than in the paracancerous non-tumor tissues. CDK13 was positively correlated with HIF-1α and negatively correlated with beclin1 in breast cancer tissues. The patients with higher expression of CDK13 showed significantly higher rates of TNM III-IV, higher rates of lymph node metastasis, distant metastasis and larger tumor size. The mortality and recurrence rates were higher in high expression CDK13 patients than in low CDK13 expression patients, however with no significant difference. K-M curve showed patients with higher CDK13 showed lower 5-year overall survival and lower disease-free survival time, however with no significant difference.
CDK13 was overexpressed in breast cancer tissues, and patients with higher CDK13 had poorer clinical outcomes. Further studies are still needed to reveal the clinical significance of CDK13 in breast cancer.
探讨细胞周期蛋白依赖性激酶13（CDK13）在乳腺癌患者中的作用及临床意义。
选取2013年3月至2015年3月期间收治的189例乳腺癌患者。采用免疫组织化学法检测CDK13、缺氧诱导因子-1α（HIF-1α）和自噬相关蛋白1（beclin1）。记录患者的年龄、体重指数（BMI）、TNM分期、病理类型及肿瘤直径等临床特征。对患者进行5年总生存期和复发情况的随访。所有患者均随访5年或至最后一次随访。
与癌旁非肿瘤组织相比，乳腺癌组织中CDK13和HIF-1α的表达水平上调，beclin1的表达水平下调。在乳腺癌组织中，CDK13与HIF-1α呈正相关，与beclin1呈负相关。CDK13高表达的患者TNM III-IV期发生率、淋巴结转移率、远处转移率显著更高，肿瘤体积更大。CDK13高表达患者的死亡率和复发率高于CDK13低表达患者，但差异无统计学意义。Kaplan-Meier曲线显示，CDK13高表达的患者5年总生存期和无病生存期较低，但差异无统计学意义。
CDK13在乳腺癌组织中过表达，CDK13高表达的患者临床结局较差。仍需进一步研究以揭示CDK13在乳腺癌中的临床意义。
